Editor-Curated Robotics Industry Briefing - RobotToday

AI-Developed Rentosertib Shows Potential to Lower Biological Age in Clinical Trial

An AI-designed drug, rentosertib, demonstrated changes in proteins linked to lower biological age in a 12-week phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). Six machine-learning aging clocks indicated biological-age reductions among participants, particularly with a 30-milligram twice-daily dosage. This finding is significant as it suggests that AI-discovered medicines may have effects beyond their primary treatment targets. While the trial involved only 42 participants and could not definitively separate the drug's anti-fibrotic effects from potential anti-aging benefits, it highlights the innovative use of AI in drug development, particularly in assessing broader impacts during clinical trials. Looking ahead, researchers emphasize the need for larger studies to further explore the drug's effects on aging processes. The study advocates for dual-purpose clinical trial designs that measure both disease-specific outcomes and aging-related endpoints, paving the way for more comprehensive evaluations of new therapies.